RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
The present invention relates to chimeric molecules comprising an oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of RNase L (&#8220;activator-antisense complex&#8221;) which specifically cleaves the ribonucleotide portion of a telomerase enzyme. The present invention relates to methods of inhibiting telomerase enzymatic activity with activator-antisense complexes targeted to the RNA component of telomerase. The present invention further relates to methods of treating malignant neoplastic disease, wherein the malignant cells contain a telomerase activity that is necessary for the growth of the malignant cells.
The Cleveland Clinic Foundation The United States of America as represented by the Department of Health and Human Services
C A A C A C
C12N A61K A61P C12N A61P C12N
additional additional inventional additional inventional inventional
Guiying Robert H. John K. Seiji Paul F.
Li Silverman Cowell Kondo Torrence